Evidentic GmbH’s Post

🚨𝗚𝗲𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝗴𝗿𝗮𝗱𝗲 𝗣𝗲𝗺𝗯𝗿𝗼𝗹𝗶𝘇𝘂𝗺𝗮𝗯💉   … from the original Keytruda® commercial drug at Evidentic! 🌐   Visit our online shop (link in the comments) to access this essential research molecule and explore our extensive batch library, featuring other licensed molecules from original therapeutics. 📊💊   Evidentic offers global access, reliable sourcing, and research benefits. Don't miss this opportunity to advance your research! 🧬🔬   #Pembrolizumab #Keytruda #ClinicalResearch #DrugDevelopment #Biotech #ResearchMolecules #Evidentic #GlobalAccess #MoleculeSupply #InnovationInScience

🌟 Are you looking for therapeutic molecules? 💊   If so, we have just what you need!   Due to special project requirements, we know sometimes the expiry date for human use is a thing. So, we decided to give you the opportunity to access the "fresh" batches from our Evidentic inventory before they become "historical". 🧬⚡️   To view our current selection of molecules and their corresponding expiration dates, please visit our website (link in the comments) or reach out to our customer support team at 📧 info@evidentic.com! 🕒 Quantities are limited, so act fast to secure the fresh molecules you need!   #InnovationInMedicine #ResearchAndDevelopment #ClinicalGradeMolecules #Evidentic #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery #Pharmaceuticals #Biotech #TherapeuticMolecules #Laboratory #BiotechSolutions #MoleculeSupply #RAndD

💊 𝐋𝐨𝐰 𝐢𝐧 𝐒𝐭𝐨𝐜𝐤 𝐑𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬! 🛒   🧪 In early drug development, researchers deal with some challenges. Don't let the access to licensed molecules be one of them.   If you're in need of small units from licensed drugs, we've got you covered. Take a look at our current selection of rare drug aliquots and see if any of our unique batches align with your research project. Additionally, we introduce the historical batches of the rare molecules that are almost out of stock and cannot be replaced. 📦💊   We encourage you to act quickly before they sell out completely. Check our online shop link in the comments! 🛒🔬   #InnovationInMedicine #ResearchAndDevelopment #ClinicalGradeMolecules #Evidentic #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery

🧠 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: 𝗔 𝗡𝗲𝘄 𝗛𝗼𝗽𝗲 𝗳𝗼𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀   The race to find effective treatments for Alzheimer's disease has produced mixed results. While the FDA has approved Aducanumab (Aduhelm®), Lecanemab (Leqmbi®), and Donanemab (Kisunla®), the European Medicines Agency (EMA) is taking a more cautious approach. ⚖️   Donanemab (Kisunla®), another promising monoclonal antibody targeting amyloid plaques, has shown promise in slowing cognitive decline in Alzheimer's patients. Approved by the FDA in 2024, it's currently under review by the EMA.   𝗡𝗲𝗲𝗱 𝗗𝗼𝗻𝗮𝗻𝗲𝗺𝗮𝗯 𝗳𝗼𝗿 𝗬𝗼𝘂𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵? 🛒 Evidentic is your sourcing specialist for licensed Donanemab, sourced directly from the original Kisunla®, and other top-quality clinical-grade molecules. 🧬 Check our online shop (link in the comments) and discover the potential of clinical-grade molecules to improve research outcomes!   #Alzheimers #Kisunla #FDA #EMA #Neuroscience #Evidentic #MonoclonalAntibodies #MABs #ClinicalGrade #DrugDevelopment #DrugDiscovery #MedicalResearch #Pharmaceuticals #ResearchandDevelopment

🎯𝗔𝗺𝗶𝘃𝗮𝗻𝘁𝗮𝗺𝗮𝗯: 𝗔 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗖𝗼𝗺𝗯𝗮𝘁𝘁𝗶𝗻𝗴 𝗡𝗦𝗖𝗟𝗖🧬   Amivantamab from the original Rybrevant® is a bispecific antibody treating non-small cell lung cancer (NSCLC) 🫁. By simultaneously targeting 🎯 the epidermal growth factor receptor (EGFR) and MET pathways, Amivantamab provides a dual-pronged approach to combatting tumor growth and metastasis. Its unique mechanism of action makes the molecule a valuable tool 🛠️ for researchers studying the complexities of NSCLC and developing innovative treatment strategies 💡.   Visit our online shop 🛒 today to access this essential research compound 🔬 and explore our batch library 📚 with other top-quality clinical-grade molecules from original therapeutics. Evidentic offers global access 🌍, reliable sourcing 🔗, and research benefits 📈. Don't miss the opportunity to advance your cancer research! 🧬   #Amivantamab #Rybrevant #NSCLC #LungCancer #EGFR #METPathways #CancerResearch #Biotechnology #InnovativeTherapies #ClinicalResearch #Evidentic #MolecularResearch #Oncology #ResearchCompounds #GlobalAccess

🧠 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: 𝗔 𝗣𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗦𝘁𝗲𝗽 𝗙𝗼𝗿𝘄𝗮𝗿𝗱   The race to find effective treatments for Alzheimer's disease has produced mixed results. While the FDA has approved Aducanumab (Aduhelm®), Lecanemab (Leqmbi®), and Donanemab (Kisunla®), the European Medicines Agency (EMA) is taking a more cautious approach. ⚖️   Lecanemab (Leqembi®), approved by the FDA in July 2024, has demonstrated potential in slowing cognitive decline in Alzheimer's patients. However, the European Medicines Agency (EMA) rejected its application, citing concerns about the balance between the observed benefits and the risks of serious side effects, such as Amyloid-related imaging abnormalities (ARIA). 🔬   𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗨𝗽𝗱𝗮𝘁𝗲 👍 MHRA Approval: The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Lecanemab, making it available to patients in the UK. 🔄 EMA Re-examination: The company behind Leqembi has requested a re-examination of the EMA's July 2024 decision. This could potentially lead to a different outcome.   𝗡𝗲𝗲𝗱 𝗟𝗲𝗰𝗮𝗻𝗲𝗺𝗮𝗯 𝗳𝗼𝗿 𝗬𝗼𝘂𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵? 🛒 Evidentic is your sourcing specialist for licensed Lecanemab , sourced directly from the original Leqembi®, and other top-quality clinical-grade molecules. 🧬 Check our online shop (link in the comments) and discover the potential of clinical-grade molecules to improve research outcomes!   #Alzheimers #Lecanemab #FDA #EMA #MHRA #Neuroscience #Evidentic #MonoclonalAntibodies #MABs #ClinicalGrade #DrugDevelopment #DrugDiscovery #MedicalResearch #Pharmaceuticals #ResearchandDevelopment

🔍𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗔𝘁𝘁𝗿𝗶𝗯𝘂𝘁𝗲𝘀 (𝗖𝗤𝗔𝘀): 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀📊   Critical Quality Attributes (CQAs) ensure the safety and efficacy of biologic products. We explain how these attributes are identified, assessed for risk, and categorized into product-specific, process-related, and obligatory groups. There are numerous CQAs for clinical-grade products delving into the structure and function of proteins and the examination of excipients.   Dr. Benjamin Müller, CEO and co-founder of the (bio)analytical company Biofidus AG, provides deeper insights in an interview on the significance of CQAs in drug development projects: https://lnkd.in/dbyb5YMY   Read more about the secrets of CQAs in our blog article: https://lnkd.in/dPwjHnqx.   #BiopharmaInsights #CQAs #BiologicQuality #EvidenticBlog #AnalyticalData #BiotechInnovation #Healthcare #QualityMatters #BioTech 🌐🧪📚🚀

🔍𝗙𝗮𝗰𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗦𝗼𝘂𝗿𝗰𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗥𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀?   No worries, you're in the right place! We're constantly expanding our network to source even the most challenging molecules to provide you with a wider range of licensed molecules, including those approved by the FDA but not yet available in the EU. 🌍   𝗪𝗵𝘆 𝗰𝗵𝗼𝗼𝘀𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝘁𝗶𝗰? 🌐 Global Reach: Access a wider variety of licensed therapeutic reference standards and biosimilars. 🕒 Time-Saving: Benefit from shorter timelines for faster product-to-market. 🔬 Quality Assurance: Boost the accuracy and reliability of your R&D with clinical-grade molecules. 🆚 Comparative Analysis: Compare EU and US material to identify the best fit for your needs. Ready to accelerate your research? Contact us today to source the therapeutic reference standards you require.   Visit our website (link in the comments) for your access to licensed molecules, biosimilars, and historical batches of original and biosimilar drugs in smaller units. 🧪   #Evidentic #ClinicalGradeMolecules #ResearchAndDevelopment #DrugDevelopment #PharmaInnovation #BiotechInnovation #HealthcareInnovation 🧪🌐💊🔬🔝

🧠 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: 𝗔 𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝘄𝗶𝘁𝗵 𝗔 𝗖𝗼𝗻𝘁𝗿𝗼𝘃𝗲𝗿𝘀𝗶𝗮𝗹 𝗦𝘁𝗮𝗿𝘁   The race to find effective treatments for Alzheimer's disease has produced mixed results. While the FDA has approved Aducanumab (Aduhelm®), Lecanemab (Leqmbi®), and Donanemab (Kisunla®), the European Medicines Agency (EMA) is taking a more cautious approach. ⚖️   Aducanumab (Aduhelm®), a monoclonal antibody, was approved by the FDA in June 2021 through a controversial accelerated procedure for the treatment of Alzheimer's disease. The decision met with widespread criticism as the drug's efficacy had not been clearly proven.🔬   The EMA rejected the application for approval in December 2021, citing insufficient data and concerns about serious side effects. 🚫   🛒 𝗡𝗲𝗲𝗱 𝗔𝗱𝘂𝗵𝗲𝗹𝗺 𝗳𝗼𝗿 𝗬𝗼𝘂𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵? Evidentic is your sourcing specialist for licensed Aducanumab, sourced directly from the original Aduhelm®, and other top-quality clinical-grade molecules. 🧬 Contact us or visit our website (link in the comments) and discover the potential of clinical-grade molecules to improve research outcomes!   #Alzheimers #Aduhelm #FDA #EMA #Neuroscience #Evidentic #MonoclonalAntibodies #MABs #ClinicalGrade #DrugDevelopment #DrugDiscovery #MedicalResearch #Pharmaceuticals #ResearchandDevelopment

🌟 𝗠𝗲𝗲𝘁 𝗦𝗼𝗳𝗶𝗮, 𝗼𝘂𝗿 𝗴𝗹𝗼𝗯𝗮𝗹 𝗽𝗿𝗼𝗯𝗹𝗲𝗺-𝘀𝗼𝗹𝘃𝗶𝗻𝗴 𝗽𝗼𝘄𝗲𝗿𝗵𝗼𝘂𝘀𝗲 🌐   Originally from Portugal, Sofia brings global expertise and connections to Evidentic 🌍 since 2021. Her diverse background in marketing 📈, operations ⚙️, and projects 📊 makes her a problem-solving whiz 🧠.   Need a molecule sourced? 🧪 Stuck on a project? 🛠️ Sofia's on it! 💼   Her in-depth knowledge across Business Development 💼, Customer Service 🤝, Logistics 🚚, and Marketing 📣 ensures smooth communication and efficient operations.   Think global connector, think Sofia! 🌎   #Evidentic #ResearchAndDevelopment #DrugDevelopment #DrugDiscovery #InterfaceManager #GlobalCitizen #Teamwork | Sofia Araujo